LEC # | TOPICS | TEXTBOOK READINGS | optional PAPERS |
---|---|---|---|
1 | Introduction Receptors / Dose-Response | pp. 3-26 | |
2 | Pharmacokinetics I Pharmacokinetics II | pp. 27-43 | |
3 | Interpreting Clinical Literature Cholinergic Pharmacology Case: Anticholinesterase | pp. 55-106, and 724-725 | Bernard, G. R., et. al. "Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis." The New England Journal of Medicine 344, no. 10 (2001): 699-709. |
4 | Drug Metabolism Pharmacogenetics Cases: Anticoagulation, Sulfasalazine | pp. 45-54, 803-809, and 350-353 | |
5 | Autonomic Pharmacology I Autonomic Pharmacology II Cases: Pheochromocytoma, Asthma | pp. 205-228, 71-86, 107-120, and 695-708 | |
6 | Local Anesthetics Antidysrhythmics Cases: Poison Control, Cocaine | pp. 205-228, 121-136, 267-284, and 719-743 | Buxton, Alfred E., et. al. "A Randomized Study of the Prevention of Sudden Death in Patients with Coronary Artery Disease." The New England Journal of Medicine 341, no. 25 (1999): 1882-1890. |
7 | Pharmacokinetics III Antiinflammatory Drugs Case: Glaucoma | pp. 781-787, and 617-646 | Weinblatt, Michael E., et. al. "A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor: Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate." The New England Journal of Medicine 340, no. 4 (1999): 253-259. Edwards, David A., et. al. "Large Porous Particles for Pulmonary Drug Delivery." Science 276, no. 5320 (1997): 1868-1871. Langer, Robert J. "New Methods of Drug Delivery." Science 249, no. 4976 (1990): 1527-1533. |
8 | Vasoactive Drugs I Vasoactive Drugs II: Heart Failure Cases: Pharmacogenetics, Thyroid Disease | pp. 285-333, 375-399, and 415-424 | Wing, Lindon M. H., et. al. "A Comparison of Outcomes with Angiotensin-converting-enzyme Inhibitors and Diuretics for Hypertension in the Elderly." The New England Journal of Medicine 348, no. 7 (2003): 583-592. The Digitalis Investigation Group. "The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure." The New England Journal of Medicine 336, no. 8 (1997): 525-533. |
9 | Lipid Lowering Drugs Cases: Placental Transfer, Gout | pp. 357-374, 447, and 709-715 | Knopp, Robert H. "Drug Treatment of Lipid Disorders." The New England Journal of Medicine 341, no. 7 (1999): 498-511. |
10 | Antihistamines Immunosuppression for Solid Organ Transplantation Cases: Antiemetics, Geriatric Pharmacology | pp. 647-654, 683-694, and 667-681 | Simons, F. Estelle R. "Advances in H1-Antihistamines." The New England Journal of Medicine 351, no. 21 (2004): 2203-2217. |
11 | Drug Development | pp. 747-756, and 791-801 | Lazo, John S., and Peter Wipf. "Combinatorial Chemistry and Contemporary Pharmacology." The Journal of Pharmacology and Experimental Therapeutics 298, no. 8 (2000): 705-709. |
12 | Neuropharmacology I: Drugs for Movement Disorders Nitric Oxide Cases: Placebo, Renal Failure | pp. 161-178, and 40 | Ichinose, Fumito, Jesse D. Roberts, Jr., and Warren M. Zapol. "Inhaled Nitric Oxide: A Selective Pulmonary Vasodilator: Current Uses and Therapeutic Potential." Circulation 109, no. 25 (2004): 3106-3111. Steudel, Wolfgang, William E. Hurford, and Warren M. Zapol. "Inhaled Nitric Oxide: Basic Biology and Clinical Applications." Anesthesiology 91, no. 4 (1990): 1090-1121. |
13 | Neuropharmacology II: Anxiolytics and Antidepressants Neuropharmacology III: Anticonvulsants Cases: Lithium, Alcohol | pp. 139-159, 179-204, and 260-261 | |
14 | Antimicrobials I Antimicrobials II Cases: Drug Allergy, Migraines | pp. 493-504, 535-544, 565-578, and 603-613 | Rodvold, Keith A. "Pharmacodynamics of Antiinfective Therapy: Taking What We Know to the Patient's Bedside." Pharmacotherapy 21, no. 11, Pt 2 (2001): 319S - 330S. |
15 | Chemotherapy I Chemotherapy II Cases: Folate, Oral Hypoglycemics | pp. 505-554, and 457-471 | |
16 | Opioids I Opioids II Cases: Cancer - Analgesia, Drug Abuse | pp. 229-263 | Kieffer, B. L. "Opioids: First Lessons from Knockout Mice." Trends in Pharmacological Sciences 20, no. 1 (1999): 19-26. |